{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:45:42Z","timestamp":1794465942846,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1038\/s41401-022-00908-4","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T07:02:29Z","timestamp":1651042949000},"page":"2993-3001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Celastrol suppresses the growth of vestibular schwannoma in mice by promoting the degradation of \u03b2-catenin"],"prefix":"10.1038","volume":"43","author":[{"given":"Na Hui","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minji","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwoo","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Byeong","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeo-Jun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Seok","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Namkung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina M.","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Dae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin-Aye","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"908_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/GIM.0b013e3181ac9a27","volume":"11","author":"DG Evans","year":"2009","unstructured":"Evans DG. Neurofibromatosis 2 [bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med. 2009;11:599\u2013610.","journal-title":"Genet Med"},{"key":"908_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2015.125","volume":"35","author":"AM Petrilli","year":"2016","unstructured":"Petrilli AM, Fernandez-Valle C. Role of merlin\/NF2 inactivation in tumor biology. Oncogene. 2016;35:537\u201348.","journal-title":"Oncogene"},{"key":"908_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-4-16","volume":"4","author":"DG Evans","year":"2009","unstructured":"Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009;4:16.","journal-title":"Orphanet J Rare Dis"},{"key":"908_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/neuonc\/noz153","volume":"22","author":"R Goldbrunner","year":"2020","unstructured":"Goldbrunner R, Weller M, Regis J, Lund-Johansen M, Stavrinou P, Reuss D, et al. EANO guideline on the diagnosis and treatment of vestibular schwannoma. Neuro Oncol. 2020;22:31\u201345.","journal-title":"Neuro Oncol"},{"key":"908_CR5","doi-asserted-by":"publisher","first-page":"E878","DOI":"10.1227\/01.NEU.0000298920.39872.62","volume":"61","author":"G Plans","year":"2007","unstructured":"Plans G, Torres A, Ferran E, Aparicio A, Acebes JJ. Contralateral hearing loss after vestibular schwannoma surgery: case report. Neurosurgery. 2007;61:E878. discussion E878.","journal-title":"Neurosurgery"},{"key":"908_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","volume":"127","author":"H Clevers","year":"2006","unstructured":"Clevers H. Wnt\/beta-catenin signaling in development and disease. Cell. 2006;127:469\u201380.","journal-title":"Cell"},{"key":"908_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4161\/org.4.2.5855","volume":"4","author":"K Nejak-Bowen","year":"2008","unstructured":"Nejak-Bowen K, Monga SP. Wnt\/beta-catenin signaling in hepatic organogenesis. Organogenesis. 2008;4:92\u20139.","journal-title":"Organogenesis"},{"key":"908_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s12276-020-0380-6","volume":"52","author":"YS Jung","year":"2020","unstructured":"Jung YS, Park JI. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond beta-catenin and the destruction complex. Exp Mol Med. 2020;52:183\u201391.","journal-title":"Exp Mol Med"},{"key":"908_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","volume":"62","author":"N Krishnamurthy","year":"2018","unstructured":"Krishnamurthy N, Kurzrock R. Targeting the Wnt\/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev. 2018;62:50\u201360.","journal-title":"Cancer Treat Rev"},{"key":"908_CR10","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36:1461\u201373.","journal-title":"Oncogene"},{"key":"908_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1593\/neo.111060","volume":"13","author":"L Zhou","year":"2011","unstructured":"Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk MA, Hanemann CO. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt\/beta-catenin signaling linked to the PDGFR\/Src and Rac\/PAK pathways. Neoplasia. 2011;13:1101\u201312.","journal-title":"Neoplasia"},{"key":"908_CR12","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/cdd.2016.54","volume":"23","author":"M Kim","year":"2016","unstructured":"Kim M, Kim S, Lee SH, Kim W, Sohn MJ, Kim HS, et al. Merlin inhibits Wnt\/beta-catenin signaling by blocking LRP6 phosphorylation. Cell Death Differ. 2016;23:1638\u201347.","journal-title":"Cell Death Differ"},{"key":"908_CR13","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/onc.2010.20","volume":"29","author":"EE Bosco","year":"2010","unstructured":"Bosco EE, Nakai Y, Hennigan RF, Ratner N, Zheng Y. NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation. Oncogene. 2010;29:2540\u20139.","journal-title":"Oncogene"},{"key":"908_CR14","doi-asserted-by":"publisher","first-page":"697","DOI":"10.5483\/BMBRep.2014.47.12.069","volume":"47","author":"HW Lee","year":"2014","unstructured":"Lee HW, Jang KS, Choi HJ, Jo A, Cheong JH, Chun KH. Celastrol inhibits gastric cancer growth by induction of apoptosis and autophagy. BMB Rep. 2014;47:697\u2013702.","journal-title":"BMB Rep"},{"key":"908_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000357683","volume":"93","author":"M Sha","year":"2014","unstructured":"Sha M, Ye J, Zhang LX, Luan ZY, Chen YB, Huang JX. Celastrol induces apoptosis of gastric cancer cells by miR-21 inhibiting PI3K\/Akt-NF-kappaB signaling pathway. Pharmacology. 2014;93:39\u201346.","journal-title":"Pharmacology"},{"key":"908_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000331729","volume":"28","author":"Y Kim","year":"2011","unstructured":"Kim Y, Kang H, Jang SW, Ko J. Celastrol inhibits breast cancer cell invasion via suppression of NF-kB-mediated matrix metalloproteinase-9 expression. Cell Physiol Biochem. 2011;28:175\u201384.","journal-title":"Cell Physiol Biochem"},{"key":"908_CR17","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.3892\/or.2014.3535","volume":"32","author":"C Mi","year":"2014","unstructured":"Mi C, Shi H, Ma J, Han LZ, Lee JJ, Jin X. Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9. Oncol Rep. 2014;32:2527\u201332.","journal-title":"Oncol Rep"},{"key":"908_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.canlet.2008.01.043","volume":"264","author":"Y Huang","year":"2008","unstructured":"Huang Y, Zhou Y, Fan Y, Zhou D. Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett. 2008;264:101\u20136.","journal-title":"Cancer Lett"},{"key":"908_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-019-1173-4","volume":"38","author":"X Liu","year":"2019","unstructured":"Liu X, Zhao P, Wang X, Wang L, Zhu Y, Song Y, et al. Celastrol mediates autophagy and apoptosis via the ROS\/JNK and Akt\/mTOR signaling pathways in glioma cells. J Exp Clin Cancer Res. 2019;38:184.","journal-title":"J Exp Clin Cancer Res"},{"key":"908_CR20","doi-asserted-by":"publisher","first-page":"175883591984373","DOI":"10.1177\/1758835919843736","volume":"11","author":"S Wang","year":"2019","unstructured":"Wang S, Ma K, Zhou C, Wang Y, Hu G, Chen L, et al. LKB1 and YAP phosphorylation play important roles in celastrol-induced beta-catenin degradation in colorectal cancer. Ther Adv Med Oncol. 2019;11:1758835919843736.","journal-title":"Ther Adv Med Oncol"},{"key":"908_CR21","doi-asserted-by":"publisher","first-page":"658092","DOI":"10.3389\/fphar.2021.658092","volume":"12","author":"CJ Zhang","year":"2021","unstructured":"Zhang CJ, Zhu N, Wang YX, Liu LP, Zhao TJ, Wu HT, et al. Celastrol attenuates lipid accumulation and stemness of clear cell renal cell carcinoma via CAV-1\/LOX-1 pathway. Front Pharmacol. 2021;12:658092.","journal-title":"Front Pharmacol"},{"key":"908_CR22","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0960-9822(03)00240-9","volume":"13","author":"MT Veeman","year":"2003","unstructured":"Veeman MT, Slusarski DC, Kaykas A, Louie SH, Moon RT. Zebrafish prickle, a modulator of noncanonical Wnt\/Fz signaling, regulates gastrulation movements. Curr Biol. 2003;13:680\u20135.","journal-title":"Curr Biol"},{"key":"908_CR23","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3390\/curroncol28010071","volume":"28","author":"M Fujii","year":"2021","unstructured":"Fujii M, Kobayakawa M, Saito K, Inano A, Morita A, Hasegawa M, et al. Rationale and design of BeatNF2 trial: a clinical trial to assess the efficacy and safety of Bevacizumab in patients with neurofibromatosis type 2 related vestibular schwannoma. Curr Oncol. 2021;28:726\u201339.","journal-title":"Curr Oncol"},{"key":"908_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/DDDT.S280069","volume":"15","author":"J Long","year":"2021","unstructured":"Long J, Zhang Y, Huang X, Ren J, Zhong P, Wang B. A review of drug therapy in vestibular schwannoma. Drug Des Dev Ther. 2021;15:75\u201385.","journal-title":"Drug Des Dev Ther"},{"key":"908_CR25","first-page":"59","volume":"8","author":"M Florescu","year":"2013","unstructured":"Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced cardiotoxicity. Maedica. 2013;8:59\u201367.","journal-title":"Maedica"},{"key":"908_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00544-7","volume":"18","author":"M Mota","year":"2020","unstructured":"Mota M, Shevde LA. Merlin regulates signaling events at the nexus of development and cancer. Cell Commun Signal. 2020;18:63.","journal-title":"Cell Commun Signal"},{"key":"908_CR27","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1158\/0008-5472.CAN-14-1952","volume":"75","author":"M Quan","year":"2015","unstructured":"Quan M, Cui J, Xia T, Jia Z, Xie D, Wei D, et al. Merlin\/NF2 suppresses pancreatic tumor growth and metastasis by attenuating the FOXM1-mediated Wnt\/beta-catenin signaling. Cancer Res. 2015;75:4778\u201389.","journal-title":"Cancer Res"},{"key":"908_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0763-9","volume":"21","author":"J Harb","year":"2019","unstructured":"Harb J, Lin PJ, Hao J. Recent development of Wnt signaling pathway inhibitors for cancer therapeutics. Curr Oncol Rep. 2019;21:12.","journal-title":"Curr Oncol Rep"},{"key":"908_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41413-018-0017-8","volume":"6","author":"B Madan","year":"2018","unstructured":"Madan B, McDonald MJ, Foxa GE, Diegel CR, Williams BO, Virshup DM. Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy. Bone Res. 2018;6:17.","journal-title":"Bone Res"},{"key":"908_CR30","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-17-2157","volume":"23","author":"A Jimeno","year":"2017","unstructured":"Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, et al. A first-in-human phase I study of the anticancer stem cell agent Ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors. Clin Cancer Res. 2017;23:7490\u20137.","journal-title":"Clin Cancer Res"},{"key":"908_CR31","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/nu9070728","volume":"9","author":"Y Li","year":"2017","unstructured":"Li Y, Li S, Meng X, Gan RY, Zhang JJ, Li HB. Dietary natural products for prevention and treatment of breast cancer. Nutrients. 2017;9:728.","journal-title":"Nutrients"},{"key":"908_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrc723","volume":"2","author":"J Mann","year":"2002","unstructured":"Mann J. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer. 2002;2:143\u20138.","journal-title":"Nat Rev Cancer"},{"key":"908_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0163-7258(03)00042-1","volume":"99","author":"L Reddy","year":"2003","unstructured":"Reddy L, Odhav B, Bhoola KD. Natural products for cancer prevention: a global perspective. Pharmacol Ther. 2003;99:1\u201313.","journal-title":"Pharmacol Ther"},{"key":"908_CR34","doi-asserted-by":"publisher","first-page":"558741","DOI":"10.3389\/fphar.2020.558741","volume":"11","author":"J Shi","year":"2020","unstructured":"Shi J, Li J, Xu Z, Chen L, Luo R, Zhang C, et al. Celastrol: a review of useful strategies overcoming its limitation in anticancer application. Front Pharmacol. 2020;11:558741.","journal-title":"Front Pharmacol"},{"key":"908_CR35","doi-asserted-by":"publisher","first-page":"5877","DOI":"10.1074\/jbc.M600072200","volume":"281","author":"H Sun","year":"2006","unstructured":"Sun H, Liu X, Xiong Q, Shikano S, Li M. Chronic inhibition of cardiac Kir2.1 and HERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking. J Biol Chem. 2006;281:5877\u201384.","journal-title":"J Biol Chem"},{"key":"908_CR36","doi-asserted-by":"publisher","first-page":"114785","DOI":"10.1016\/j.taap.2019.114785","volume":"383","author":"C Liu","year":"2019","unstructured":"Liu C, Zhang C, Wang W, Yuan F, He T, Chen Y, et al. Integrated metabolomics and network toxicology to reveal molecular mechanism of celastrol induced cardiotoxicity. Toxicol Appl Pharmacol. 2019;383:114785.","journal-title":"Toxicol Appl Pharmacol"},{"key":"908_CR37","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.3390\/molecules24112162","volume":"24","author":"C Jin","year":"2019","unstructured":"Jin C, Wu Z, Wang L, Kanai Y, He X. CYP450s-activity relations of celastrol to interact with Triptolide reveal the reasons of hepatotoxicity of Tripterygium wilfordii. Molecules. 2019;24:2162.","journal-title":"Molecules"},{"key":"908_CR38","doi-asserted-by":"crossref","unstructured":"Sun M, Tang Y, Ding T, Liu M, Wang X. Inhibitory effects of celastrol on rat liver cytochrome P450 1A2, 2C11, 2D6, 2E1 and 3A2 activity. Fitoterapia. 2014;92:1\u20138.","DOI":"10.1016\/j.fitote.2013.10.004"},{"key":"908_CR39","doi-asserted-by":"publisher","first-page":"e35733","DOI":"10.1371\/journal.pone.0035733","volume":"7","author":"S Kusy","year":"2012","unstructured":"Kusy S, Ghosn EE, Herzenberg LA, Contag CH. Development of B cells and erythrocytes is specifically impaired by the drug celastrol in mice. PLoS One. 2012;7:e35733.","journal-title":"PLoS One"},{"key":"908_CR40","doi-asserted-by":"publisher","first-page":"7880","DOI":"10.3390\/molecules16097880","volume":"16","author":"J Song","year":"2011","unstructured":"Song J, Shi F, Zhang Z, Zhu F, Xue J, Tan X, et al. Formulation and evaluation of celastrol-loaded liposomes. Molecules. 2011;16:7880\u201392.","journal-title":"Molecules"},{"key":"908_CR41","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/10717544.2018.1425778","volume":"25","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Tan Y, Meng T, Liu X, Zhu Y, Hong Y, et al. Simultaneous targeting therapy for lung metastasis and breast tumor by blocking the NF-kappaB signaling pathway using celastrol-loaded micelles. Drug Deliv. 2018;25:341\u201352.","journal-title":"Drug Deliv"},{"key":"908_CR42","first-page":"3023","volume":"7","author":"Y Chen","year":"2012","unstructured":"Chen Y, Zhou L, Yuan L, Zhang ZH, Liu X, Wu Q. Formulation, characterization, and evaluation of in vitro skin permeation and in vivo pharmacodynamics of surface-charged tripterine-loaded nanostructured lipid carriers. Int J Nanomed. 2012;7:3023\u201332.","journal-title":"Int J Nanomed"},{"key":"908_CR43","doi-asserted-by":"publisher","first-page":"6835","DOI":"10.2147\/IJN.S93752","volume":"10","author":"V Sanna","year":"2015","unstructured":"Sanna V, Chamcheu JC, Pala N, Mukhtar H, Sechi M, Siddiqui IA. Nanoencapsulation of natural triterpenoid celastrol for prostate cancer treatment. Int J Nanomed. 2015;10:6835\u201346.","journal-title":"Int J Nanomed"},{"key":"908_CR44","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4161\/cbt.11.2.13959","volume":"11","author":"SM Raja","year":"2011","unstructured":"Raja SM, Clubb RJ, Ortega-Cava C, Williams SH, Bailey TA, Duan L, et al. Anticancer activity of celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther. 2011;11:263\u201376.","journal-title":"Cancer Biol Ther"},{"key":"908_CR45","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3389\/fphar.2018.00365","volume":"9","author":"MK Shanmugam","year":"2018","unstructured":"Shanmugam MK, Ahn KS, Lee JH, Kannaiyan R, Mustafa N, Manu KA, et al. Celastrol attenuates the invasion and migration and augments the anticancer effects of Bortezomib in a xenograft mouse model of multiple myeloma. Front Pharmacol. 2018;9:365.","journal-title":"Front Pharmacol"},{"key":"908_CR46","first-page":"984","volume":"19","author":"UM Nazim","year":"2019","unstructured":"Nazim UM, Yin H, Park SY. Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAILinduced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species. Mol Med Rep. 2019;19:984\u201393.","journal-title":"Mol Med Rep"},{"key":"908_CR47","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00280-019-03900-8","volume":"84","author":"Z Cha","year":"2019","unstructured":"Cha Z, Cheng J, Xiang H, Qin J, He Y, Peng Z, et al. Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway. Cancer Chemother Pharmacol. 2019;84:719\u201328.","journal-title":"Cancer Chemother Pharmacol"},{"key":"908_CR48","first-page":"441","volume":"27","author":"JH Lee","year":"2011","unstructured":"Lee JH, Choi KJ, Seo WD, Jang SY, Kim M, Lee BW, et al. Enhancement of radiation sensitivity in lung cancer cells by celastrol is mediated by inhibition of Hsp90. Int J Mol Med. 2011;27:441\u20136.","journal-title":"Int J Mol Med"},{"key":"908_CR49","doi-asserted-by":"publisher","first-page":"e0178204","DOI":"10.1371\/journal.pone.0178204","volume":"12","author":"HY Jun","year":"2017","unstructured":"Jun HY, Kim TH, Choi JW, Lee YH, Lee KK, Yoon KH. Evaluation of connectivity map-discovered celastrol as a radiosensitizing agent in a murine lung carcinoma model: feasibility study of diffusion-weighted magnetic resonance imaging. PLoS One. 2017;12:e0178204.","journal-title":"PLoS One"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-00908-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-00908-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-00908-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:06:40Z","timestamp":1667261200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-00908-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["908"],"URL":"https:\/\/doi.org\/10.1038\/s41401-022-00908-4","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"22 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}